Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 84
Filtrar
1.
Neurol Sci ; 2024 Jul 05.
Artigo em Inglês | MEDLINE | ID: mdl-38967881

RESUMO

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscle weakness. Presence of pain in ALS patients is heterogeneously reported in studies, and mostly underrepresented in symptom scales. The aim of this study is to evaluate the efficacy of pharmacological and non-pharmacological therapeutic modalities for pain management in patients with ALS. A systematic review was conducted in four databases; PubMed, Scopus, Clinicaltrials.gov, and Cochrane-Ovid. Five randomized controlled clinical trials were included regarding pharmacological and non-pharmacological pain management interventions in adult patients with confirmed diagnosis of ALS in whom pain was objectively evaluated. Risk of bias assessment was evaluated using the RoB2.0 tool. Eligible studies were reported as a descriptive analysis. This systematic review was registered with PROSPERO ID: CRD42024495009. Five clinical trials regarding pain management strategies in ALS were eligible for analysis. Two out of five were non-pharmacological approaches whilst the remaining three provided pharmacological therapies. Of these, Mexiletine was efficient in terms of pain relief, particularly between 600 and 900 mg per day, whereas Mecasin showed no pain relief at both, high and low doses. Non-pharmacological therapies, such as exercise and osteopathic manual treatment also lacked efficacy in regard to pain management. Clinical trials focusing on pain management strategies for ALS patients are limited. Medical professionals, understandably focused on immediate life-threatening aspects, may inadvertently sideline the nuanced and intricate dimension of pain experienced by patients with ALS.

2.
Disaster Med Public Health Prep ; 18: e31, 2024 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-38379429

RESUMO

BACKGROUND: Community-based medication therapy management advanced pharmacy practice experiences (MTM APPE) can engage pharmacy students in public health initiatives, including emergency response preparedness, to successfully impact patient care. This study aimed to evaluate pharmacy students' perceptions of their experience on an MTM APPE during disasters in Puerto Rico. METHODS: After completing the MTM APPE during times of hurricanes, earthquake or pandemic, pharmacy students were asked to voluntarily participate in a questionnaire about their perception of assisting during a disaster. The survey consisted of 5 questions. Four questions were based on a Likert scale with answers choices ranging from Agree, Not Sure, Disagree, or Not Applicable. One question requested free text comments from participants. RESULTS: Sixteen students completed the survey. Pharmacy students agreed that the MTM APPE taught them the clinical skills needed to assist and educate individual patients and the community that suffered from a disaster, and that the role of the pharmacist is vital when a disaster disrupts a community's health-care system. CONCLUSIONS: Training in emergency response to disasters should be a considered component of MTM APPE.


Assuntos
Tempestades Ciclônicas , Desastres , Terremotos , Educação em Farmácia , Farmácia , Estudantes de Farmácia , Humanos , Conduta do Tratamento Medicamentoso/educação , Porto Rico , Pandemias , Currículo
3.
J Comp Eff Res ; 13(4): e230127, 2024 04.
Artigo em Inglês | MEDLINE | ID: mdl-38329429

RESUMO

Aim: Comprehensive medication management (CMM) is a clinical service that aims to optimize the therapeutic results of patients at the individual level. Studies carried out in Brazil and in several parts of the world have found a positive impact of the service, mainly in the resolution of drug therapy problems and in improving clinical outcomes and patients' quality of life. This service is not widespread and its acceptability and willingness to pay were not defined by the population yet. Objective: This work aims to conduct a study with users of private health services to determine the acceptability and willingness to pay for CMM services. Methods: This is a cross-sectional survey conducted through face-to-face interviews, among residents over 18 years of age of the metropolitan region of Belo Horizonte, capital of Minas Gerais State, Brazil. Results: For this study, 563 individuals were interviewed. Most respondents were female (55.1%), had completed high school (46.8%) and were employed (62.5%). The acceptability for the service was 93,25%, and among all respondents, 37 would not accept the service even if it was free. The amount of consumers' willingness to pay for the CMM service was estimated at $17.75 (40.00 BRL). Conclusion: The research results show that most people are willing to pay for the CMM service. This study can contribute to the decision-making regarding the implementation and pricing of the service in Brazil.


Assuntos
Conduta do Tratamento Medicamentoso , Qualidade de Vida , Humanos , Feminino , Adolescente , Adulto , Masculino , Brasil , Estudos Transversais , Inquéritos e Questionários
4.
Braz. j. med. biol. res ; 57: e12937, fev.2024. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1534073

RESUMO

The treatment of arterial hypertension (AH) contributes to the reduction of morbidity and mortality. Gender differences are likely to play a role, as non-treatment is associated with clinical and sociodemographic aspects. The aim of this study was to investigate the factors associated with non-treatment of AH and gender differences in hypertensive individuals from the ELSA-Brasil cohort. The study was conducted with 5,743 baseline hypertensive cohort participants. AH was considered if there was a previous diagnosis or if systolic blood pressure (SBP) was ≥140 and/or diastolic BP (DBP) was ≥90 mmHg. Sociodemographic and anthropometric data, lifestyle, comorbidities, and use of antihypertensive medications were evaluated through interviews and in-person measurements. Treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) or other antihypertensive medications and non-treatment were evaluated with multivariate logistic regression. Non-treatment was observed in 32.8% of hypertensive individuals. Of the 67.7% treated individuals, 41.1% received RAASi. Non-treatment was associated with alcohol consumption in women (OR=1.41; 95%CI: 1.15-1.73; P=0.001), lowest schooling level in men (OR=1.70; 95%CI: 1.32-2.19; P<0.001), and younger age groups in men and women (strongest association in males aged 35-44 years: OR=4.58, 95%CI: 3.17-6.6, P<0.001). Among those using RAASi, a higher proportion of white, older individuals, and with more comorbidities was observed. The high percentage of non-treatment, even in this civil servant population, indicated the need to improve the treatment cascade for AH. Public health policies should consider giving special attention to gender roles in groups at higher risk of non-treatment to reduce inequities related to AH in Brazil.

5.
J Pediatr ; 266: 113813, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-37918519

RESUMO

OBJECTIVES: To assess the presence and timing of furosemide diuretic tolerance in infants with bronchopulmonary dysplasia (BPD), and to determine if tolerance is modified by thiazide co-administration. STUDY DESIGN: We performed a retrospective cohort study among infants born very preterm with BPD exposed to repeated-dose furosemide for 72 hours, measuring net fluid balance (total intake minus total output) as a surrogate of diuresis in the 3 days before and after exposure. The primary comparison was the difference in fluid balance between the first and third 24 hours of furosemide exposure. We fit a general linear model for within-subject repeated measures of fluid balance over time, with thiazide co-administration as an interaction variable. Secondary analyses included an evaluation of weight trajectories over time. RESULTS: In 83 infants, median fluid balance ranged between + 43.6 and + 52.7 ml/kg/d in the 3 days prior to furosemide exposure. Fluid balance decreased to a median of + 29.1 ml/kg/d in the first 24 hours after furosemide, but then increased to +47.5 ml/kg/d by the third 24-hour interval, consistent with tolerance (P < .001). Thiazides did not modify the change in fluid balance during furosemide exposure for any time-period. Weight decreased significantly in the first 24 hours after furosemide and increased thereafter (P < .001). CONCLUSIONS: The net fluid balance response to furosemide decreases rapidly during repeated-dose exposures in infants with BPD, consistent with diuretic tolerance. Clinicians should consider this finding in the context of an infant's therapeutic goals. Further research efforts to identify safe and effective furosemide dosage strategies are needed.


Assuntos
Displasia Broncopulmonar , Doenças do Prematuro , Recém-Nascido , Humanos , Diuréticos/uso terapêutico , Furosemida , Displasia Broncopulmonar/tratamento farmacológico , Lactente Extremamente Prematuro , Estudos Retrospectivos , Doenças do Prematuro/tratamento farmacológico , Tiazidas/uso terapêutico
6.
Evid. actual. práct. ambul. (En línea) ; 27(1): e007117, 2024. tab
Artigo em Espanhol | LILACS, BINACIS, UNISALUD | ID: biblio-1552325

RESUMO

Así como planteamos en la primera entrega de esta serie de artículos de actualización sobre la obesidad, resulta urgente revisar el abordaje tradicional que la comunidad médica le ofrece a las personas con cuerpos gordos. En este segundo artículo desarrollaremos en profundidad diferentes alternativas terapéuticas para los pacientes que desean bajar de peso:plan alimentario, actividad física, tratamiento farmacológico y cirugía metabólica. (AU)


As we proposed in the first issue of this series of articles, it is urgent to review the traditional approach that the medical community offers to people with fat bodies. This second article will develop different therapeutic alternatives for patients who want to lose weight: eating plans, physical activity, pharmacological treatment, and metabolic surgery. (AU)


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Exercício Físico , Bupropiona/administração & dosagem , Dieta , Sobrepeso/terapia , Cirurgia Bariátrica , Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Naltrexona/administração & dosagem , Obesidade/terapia , Índice de Massa Corporal , Bupropiona/efeitos adversos , Receptor do Peptídeo Semelhante ao Glucagon 1/administração & dosagem , Estilo de Vida Saudável , Preconceito de Peso , Alimento Processado , Naltrexona/efeitos adversos
7.
Saúde Pesqui. (Online) ; 16(4): 11966, out./dez. 2023.
Artigo em Inglês, Português | LILACS-Express | LILACS | ID: biblio-1524119

RESUMO

Avaliar os resultados clínicos de serviços de gerenciamento da terapia medicamentosa (GTM) oferecidos a pessoas vivendo com HIV (PVHIV) em uma unidade de dispensação de medicamentos brasileira. O estudo foi dividido em uma etapa transversal (etapa I), que avaliou o fator associado à identificação de dois ou mais problemas relacionados ao uso de medicamentos (PRM) na avaliação inicial; e uma etapa quasi- experimental (etapa II), realizada com um único grupo de pacientes para avaliar desfechos clínicosForam acompanhadas 52 PVHIV. A média de idade foi de 60±11,3 anos (min. = 29; máx. =78). A presença de dislipidemia (OR=5,38; IC 95%=1,61-17,97; p=0,006) e o uso de sete ou mais medicamentos (OR=4,28; IC 95%=1,32-13,88; p=0,015) foram fatores associados a identificação de dois ou mais PRM. Foi demonstrada uma diferença significativa entre os valores iniciais e finais de pressão arterial sistólica, carga viral do HIV, contagem de células T CD4+ e triglicerídeos (p<0,05). O serviço de GTM favoreceu os desfechos clínicos positivos.


To assess the clinical outcomes of comprehensive medication management (CMM) services offered to people living with HIV (PLHIV) at a Brazilian Antiretroviral Medication Dispensing Unit. The study was divided into a cross-sectional stage (stage I), to evaluate associated factor with the identification of two or more drug therapy problems (DTP) in the initial assessment; and a quasi-experimental stage (stage II), conducted with a single group of PLHIV to evaluate clinical outcomes. A total of 52 PLHIV, with 60±11.3 years of age were followed up. In stage I, the presence of dyslipidemia (OR=5.38; 95%CI=1.61-17.97) and the use of seven or more medications (OR=4.28; 95% CI=1.32-13.88) were factors associated with the identification of DTP. In stage II, a significant difference was demonstrated between the initial and final values of systolic blood pressure, triglycerides, HIV viral load and CD4+T-cells count (p<0,05). The CMM service favored positive clinical outcomes.

8.
An Bras Dermatol ; 98(6): 814-836, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37302894

RESUMO

This publication is an update of the "Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology" published in 2019, considering the novel, targeted-oriented systemic therapies for atopic dermatitis. The initial recommendations of the current consensus for systemic treatment of patients with atopic dermatitis were based on a recent review of scientific published data and a consensus was reached after voting. The Brazilian Society of Dermatology invited 31 experts from all regions of Brazil and 2 international experts on atopic dermatitis who fully contributed to the process. The methods included an e-Delphi study to avoid bias, a literature search and a final consensus meeting. The authors added novel approved drugs in Brazil and the indication for phototherapy and systemic therapy for AD. The therapeutical response to systemic treatment is hereby reported in a suitable form for clinical practice and is also part of this updated manuscript.


Assuntos
Dermatite Atópica , Dermatologia , Humanos , Brasil , Técnica Delphi , Dermatite Atópica/tratamento farmacológico , Consenso , Fototerapia
9.
Rev. Flum. Odontol. (Online) ; 2(61): 59-68, maio-ago. 2023.
Artigo em Português | LILACS, BBO - Odontologia | ID: biblio-1562619

RESUMO

A dor é a queixa principal dos pacientes com disfunção temporomandibular ­ DTM- e seu controle deve ter prioridade absoluta no tratamento das DTM. A intervenção farmacológica tem sido utilizada por muitos anos. A escolha de um medicamento para o alívio da dor está diretamente relacionada ao estágio e a intensidade relatada pelo paciente, determinando que classes de drogas são eficazes, o período de utilização e efeitos colaterais. As principais classes medicamentosas utilizadas incluem: analgésicos, relaxantes musculares, anti-inflamatórios não esteroidais (AINES), antidepressivos, ansiolíticos, anticonvulsivantes, corticosteroides. O objetivo desta revisão é de abordar os principais agentes farmacológicos utilizados como coadjuvantes no tratamento de pacientes com sintomatologia dolorosa decorrente da DTM, além de analisar o raciocínio farmacológico envolvido na prescrição de cada classe de fármaco em cada tipo dor. Artigos entre 1955 e 2021, foram selecionados através das principais bases de dados como BV Salud, Scielo e Pubmed. Foram incluídos na lista de elegibilidade, artigos relacionados ao tema terapia medicamentosa no controle de dor em pacientes com DTM, dando ênfase às classes medicamentosas anteriormente mencionadas. Artigos que não possuíam texto completo ou o resumo não se referia diretamente ao tema foram excluídos. Em síntese, essa análise serve como forma de agregar conhecimento do ponto de vista teórico e auxiliar o prescritor na escolha do melhor fármaco para cada paciente, levando em consideração o tipo, duração e intensidade de cada caso, para que posteriormente, haja uma tratativa definitiva do caso.


Pain is the main complaint in patients with temporomandibular disorders - TMD - and its control should have absolute priority in the treatment of TMD. Pharmacological intervention has been used for many years. The choice of medication that will be used for pain relief is directly related to the stage and intensity reported by the patient, and these will determine which classes of drugs are effective, the period of use and the adverse effects. The usual drug classes used includes: analgesics, muscle relaxants, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, anxiolytics, anticonvulsants, corticosteroidsThe objective of this eview is to approach the most common pharmacological agents used as adjuncts in the treatment of patients with painful symptoms resulting from TMD, and further to analyze the pharmacological logic. Articles between 1955 and 2021 were selected through the BV Salud, Scielo and Pubmed databases. Articles related to the topic "drug therapy in pain control in patients with TMD" will be included in the eligibility list, emphasizing the previously mentioned drug classes. Articles that didn't have full text or the abstract didn't directly refered to the topic were excluded. In this way, this literature review serves as a way of adding knowledge from a theoretic point of view and help the prescriber on choosing the best drug for each patient, taking into account the type, duration and intensity of each case, so that later, there is a definitive treatment of the case.


Assuntos
Dor Facial , Síndrome da Disfunção da Articulação Temporomandibular , Conduta do Tratamento Medicamentoso
10.
Pharmacy (Basel) ; 11(1)2023 Feb 16.
Artigo em Inglês | MEDLINE | ID: mdl-36827675

RESUMO

Implementing Comprehensive Medication Management (CMM) services uncovered the importance of the totality of the patient's perspective in this process. The holistic approach takes into account the physical, mental and emotional well-being of individuals, as well as their socioeconomic circumstances. The aim of this study was to characterize the scientific evidence associated with CMM services that included this holistic approach. A scoping review was conducted based on Arksey and O'Malley's method. Searches were performed in Google Scholar for papers published between 2010 and 2020 in English, Spanish and Portuguese. Study design, health contexts, sample of patients, results obtained, barriers and facilitators, and the integration of a holistic approach were determined. Two hundred and eighteen papers were evaluated, most of which focused on the implementation of this service through prospective observational studies. A minority of studies reported on a holistic approach, a smaller number examined the effect of social determinants of health, the patient's medication experiences and the pharmacotherapy outcomes from the patient's perspective. Despite the progress achieved, most of the referents do not yet reflect a broader view of the patient's life situation and its relationship to pharmacotherapy and the ways in which the pharmacist implements holistic elements to solve or prevent drug-related problems.

12.
J Oncol Pharm Pract ; 29(2): 375-385, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35037789

RESUMO

INTRODUCTION: Allogeneic Hematopoietic Stem Cells Transplantation (allo-HSCT) is capable of curing patients with neoplastic or non-neoplastic hematologic disorders or of prolonging their survival. This study assessed if the insertion of the clinical pharmacist in the allo-HSCT team modified the outcomes: transplantation-related mortality, grafting failure, incidence of Graft versus Host Disease, hospitalization time, time for grafting, number of readmissions, number of drug-related problems (DRPs), adherence and knowledge about pharmacotherapy. METHODS: Interventional study with historical control carried out in an allo-HSCT unit, in which the intervention group (IG) included 33 individuals who received pharmacotherapy follow-up. Control Group (CG) consisted of 28 individuals. RESULTS: A total of 250 DRPs were identified, 59 team's doubts were clarified, and 309 interventions were conducted in the IG. The DRPs mainly arose from safety (51.60%) and effectiveness (38.40%) problems. A mean of 9.36 (SD = 6.97) interventions per patient was obtained, mainly including dose reductions (19.09%), adjustments in administration time (18.12%), educational activities (15.21%) and drug removal (10.68%). Clinical significance of the interventions was considered high (75.7% extremely significant, very significant or significant), as well as their acceptability (89.7% accepted). Each patient attended a mean of 4.68 pharmaceutical consultations (SD = 1.91) after hospital discharge, presenting increase in knowledge (p = 0.0001) and in adherence (p = 0.0115). There was no evidence of differences between the groups in the other outcomes analyzed. CONCLUSIONS: The pharmacotherapy follow-up allowed detecting several DRPs and performing interventions of high clinical relevance and acceptability, in addition to improving adherence and individualizing the pharmacotherapy.


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Humanos , Farmacêuticos , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Hospitalização , Doença Enxerto-Hospedeiro/prevenção & controle , Doença Enxerto-Hospedeiro/etiologia , Células-Tronco Hematopoéticas , Estudos Retrospectivos
13.
An. bras. dermatol ; An. bras. dermatol;98(6): 814-836, 2023. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1520040

RESUMO

Abstract This publication is an update of the "Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology" published in 2019, considering the novel, targeted-oriented systemic therapies for atopic dermatitis. The initial recommendations of the current consensus for systemic treatment of patients with atopic dermatitis were based on a recent review of scientific published data and a consensus was reached after voting. The Brazilian Society of Dermatology invited 31 experts from all regions of Brazil and 2 international experts on atopic dermatitis who fully contributed to the process. The methods included an e-Delphi study to avoid bias, a literature search and a final consensus meeting. The authors added novel approved drugs in Brazil and the indication for phototherapy and systemic therapy for AD. The therapeutical response to systemic treatment is hereby reported in a suitable form for clinical practice and is also part of this updated manuscript.

14.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1533680

RESUMO

Introducción: El uso del acenocumarol como anticoagulante, constituye un aporte al tratamiento de la fibrilación auricular no valvular. En la actualidad existen otros tipos de anticoagulantes que no requieren control tan exhaustivo de la prueba digital International Normaizedl Ratio y tienen menos efectos secundarios. España es uno de los pocos países de Europa que continúa indicando acenocumarol, de forma similar a la warfarina. Tanto es así, que a los médicos de atención primaria no se les permite prescribir otros anticoagulantes más eficaces y menos molestos, para el paciente al realizar la prueba digital. Objetivo: Analizar el uso inadecuado del fármaco acenocumarol en la fibrilación auricular no valvular. Métodos: Se realizó un estudio exploratorio, en un sistema de salud de atención primaria y hospitales de categoría secundaria. La población la integraron 2 650 habitantes del sureste español con fibrilación auricular no valvular, tomadores de acenocumarol con seguimiento de 12 meses. Resultados: Se consideró las variaciones y labilidad del valor International Normalized Ratio, entre 2,0-3,0 en determinaciones cada 28 días, no obstante a la enfermedad cardiovascular y cifras obtenidas respecto a las anteriores. El tiempo de seguimiento fue 12 meses y desapareció la fragilidad, se tomaron muestras cada 28 días. Antes de finalizar el estudio, desapareció la labilidad del International Normalized Ratio durante más de tres meses en 53 (97,95 %) de los pacientes. Dado que la mayoría de los enfermos que consumían acenocumarol tenían edades por encima de 65 años y estaban sometidos a régimen de poli medicación, los medicamentos que consumían, fueron motivo de evaluación. Conclusiones: El tiempo transcurrido entre la determinación del International Normaizedl Ratio y la última ingesta de alimentos y medicamentos, no fue correcto, existe tendencia a realizar determinaciones anárquicas del International Normalized Ratio, sin investigaciones relacionadas con fármacos consumidos junto al acenocumarol.


Introduction: The use of acenocoumarol as an anticoagulant represents a contribution to the treatment of non-valvular atrial fibrillation. At present, there are other types of anticoagulants that do not require such exhaustive control of the International Normalized Ratio digital test and have fewer side effects. Spain is one of the few countries in Europe that continues to prescribe acenocoumarol, which is similar to warfarin. So much so that primary care physicians are not allowed to prescribe other more effective and less troublesome anticoagulants for the patient when performing the digital test. Objective: To analyze the inappropriate use of the drug acenocoumarol in non-valvular atrial fibrillation. Methods: An exploratory study was carried out in a primary health care system and secondary category hospitals. The population consisted of 2650 inhabitants of southeastern Spain with non-valvular atrial fibrillation, taking acenocoumarol with 12 months follow-up. Results: We considered the variations and lability of the International Normalized Ratio value, between 2.0-3.0 in determinations every 28 days, regardless of cardiovascular disease and figures obtained in relation to the previous. The follow-up time was 12 months and the lability disappeared, samples were taken every 28 days. Before the end of the study, the lability of the International Normalized Ratio disappeared for more than three months in 53 (97.95%) of the patients. Since most of the patients taking acenocoumarol were over 65 years of age and on polymedication, the medications taken by each of them were evaluated. Conclusions: The time elapsed between the International Normalized Ratio determination and the last intake of food and medication was not correct, and there is a tendency to perform anarchic determinations of the International Normalized Ratio without investigations related to drugs consumed together with acenocoumarol.

15.
Pharmacy (Basel) ; 10(6)2022 Nov 14.
Artigo em Inglês | MEDLINE | ID: mdl-36412827

RESUMO

Comprehensive medication management (CMM) is the service offered within the clinical practice of pharmaceutical care, which has the objective to optimize pharmacotherapeutic outcomes. Patient satisfaction is a multidimensional construct that points to the quality of the health services offered and the degree to which the patients' expectations and needs are met. The evaluation of the level of patient satisfaction is a key indicator to support decisions and to improve the quality of the service provided. This study aims to describe the protocol for a scoping review to map the instruments to measure patient satisfaction with CMM services and compare them according to their development characteristics and the applicability of patient-reported outcome measures. The literature search will be conducted using the scoping review methodology, proposed by the Joanna Briggs Institute and the PRISMA Extension for Scoping Reviews (PRISMA-ScR) method. The results will be presented in two sessions: (1) description of the search strategy; and (2) the characteristics of the satisfaction instruments, number of items and questions related to the conceptual model, content validity, construct validity, reliability, score/interpretation, and respondent burden. This review will shed light on the available satisfaction measurement instruments, allowing existing gaps to be identified for future research.

16.
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1359088

RESUMO

Objective: to describe the implementation and to assess the effectiveness of a pilot integrated qualification program to improve the medication use in a long-term care facility (LTCF). Methods: This was a type 1 hybrid effectiveness-implementation study. A pilot integrated qualification program to improve the medication use in a LTCF was carried out by implementing a new drug distribution system and a comprehensive medication management (CMM) service according to the following four steps: I) implementation of the drug distribution system followed by the evaluation of the health team's opinion; II) prescription review with the identification of potential drug therapy problems (PDTPs); III) provision of the CMM service according to the framework of Pharmaceutical Care practice within one year; and, IV) evaluation of the effectiveness of the program through the comparison of clinical and laboratory parameters (blood pressure, glycated hemoglobin and lipid fractions) using the t-test or Wilcoxon signed-rank test. Results: In step I, the distribution system was fully outsourced to a company that furnished all solid oral dosage forms in individual boxes containing a plastic coil with multiple envelopes for 30 days. In step II, 180 PDTPs were identified, and all patients presented with at least one of them. In step III, after the first assessment of the CMM Service, 43 actual drug therapy problems (DTPs) were identified. After one year of service provision, 96 DTPs were identified and 75.8% of them were resolved (n=72). In step IV, a statistically significant difference was observed between the initial and final minimum and maximum systolic and diastolic blood pressure (p<0,05). Conclusions: The pilot integrated qualification program had a positive impact on the clinical parameters. The global population is rapidly aging, making this type of study important to exemplify a multifaceted strategy to improve the quality of drug therapy for institutionalized patients.

17.
Curr Drug Saf ; 17(3): 183-192, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-34649491

RESUMO

BACKGROUND: Extemporaneous compounding (EC) involves the preparation of a therapeutic product for specific patient need. However, there is a potential relationship between this procedure and the occurrence of health incidents (HI). The use of trigger tools increases HI identification. OBJECTIVE: This study assessed the performance of EC as a trigger to detect potential health incidents arising from this procedure. METHODS: A one-month observational and cross-sectional study was performed in internal medicine ward and intensive care unit of medium-sized hospital. Data collection was carried out in 5 stages: all triggered patients with dysphagia or enteral feeding tube with prescription of EC were included; EC executed in prescribed standardized drugs was observed; the procedure was compared with the hospital guide and scientific literature; HI monitoring and their evaluation using WHO and NCC MERP algorithms; a search for pharmaceutical alternatives (PA) that would avoid the observed EC. RESULTS: 197 patients were recruited. Almost half of them were triggered by EC from 84 standardized drugs. 48 patients met the inclusion criteria. 28 adverse drug reactions, 01 therapeutic ineffectiveness, and 29 medication errors were identified. EC as a trigger tool showed a PPV value of 0.38. Only 24 drugs have PA available in the market, which could avoid one third of all observed EC. CONCLUSION: It was possible to detect potentially HI in one of two patients with enteral feeding tubes using EC as a trigger tool. The use of EC as a trigger tool contributes to identifying potential HI arising from drugs, which have not gotten pharmaceutical alternatives to be administered via enteral feeding tube.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Erros de Medicação , Estudos Transversais , Composição de Medicamentos , Humanos , Erros de Medicação/prevenção & controle , Preparações Farmacêuticas
18.
J Oncol Pharm Pract ; 28(1): 135-140, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34661492

RESUMO

Radioiodine therapy can be used in differentiated thyroid carcinoma and requires extensive evaluation to ensure effectiveness and safety. Therefore, it is necessary to evaluate all health problems and medications used in the pre-radioiodine therapy period and comprehensive medication managementservices can serve as a screening tool in this context. The present study aims to describe critical clinical situations identified during the initial assessments of a comprehensive medication management service offered to differentiated thyroid carcinoma patients pre-radioiodine therapy, and the pharmaceutical interventions performed to solve them. A descriptive study with regard to the initial ten months of a comprehensive medication management service was carried out in a large oncology hospital (Rio de Janeiro, Brazil). Descriptive analysis was used to describe the critical clinical situations identified, as well as the correspondent drug therapy problems and the type, acceptability, and outcomes of the pharmaceutical interventions performed to solve them. Thirty patients with an average of 45.8 years and 5.1 medications were evaluated. Five critical clinical situations were identified; corresponding to drug therapy problems two(needs additional drug therapy - n = 4) and drug therapy problems four (dosage too low - n = 1). All pharmaceutical interventions were accepted. The comprehensive medication management service provision pre-radioiodine therapy is feasible and represents an important screening strategy.


Assuntos
Preparações Farmacêuticas , Serviço de Farmácia Hospitalar , Farmácia , Brasil , Humanos , Radioisótopos do Iodo/uso terapêutico
19.
Cogitare Enferm. (Online) ; 27: e83599, 2022. tab
Artigo em Português | LILACS, BDENF - Enfermagem | ID: biblio-1404362

RESUMO

RESUMO Objetivo: Identificar o volume residual em frascos-ampola, após o preparo de injetáveis, associando os erros relacionados a subdoses com as classes dos medicamentos. Método: Estudo descritivo, de abordagem quantitativa. Os dados foram coletados no período de dezembro de 2020 a setembro de 2021, em um serviço ambulatorial privado de um município brasileiro localizado a nordeste do Estado de São Paulo. Foram analisados 562 frascos-ampola de medicamentos preparados pela equipe de enfermagem. Utilizou-se formulário contendo o nome comercial do medicamento, classe/indicação terapêutica, data e horário de reconstituição, volume utilizado para reconstituição do medicamento e volume residual de cada frasco. Os dados foram tabulados e analisados por estatística descritiva e teste ANOVA. Resultados: 462 (82,2%) frascos-ampola continham volume residual que variou de 0,1 ml a 1,5 ml e 165 (29,4%) continham 0,2 ml de solução residual, com perda média de 4,5% da solução. Não houve diferença na perda de solução entre as diferentes classes de medicamentos. Conclusão: Os achados destacam a necessidade de intervenções para a redução de falhas, nas fases de preparo dos medicamentos, com ênfase nos erros associados às subdosagens terapêuticas.


ABSTRACT Objective: Identify the residual volume in ampoule-vials after the preparation of injectables, associating the errors related to underdosing with the classes of drugs. Method: This is a descriptive study with a quantitative approach. Data were collected between December 2020 and September 2021, in a private outpatient service located in a Brazilian municipality in the northeast of the state of São Paulo. A total of 562 ampoule-vials of medications prepared by a nursing staff were analyzed. A form was used containing the commercial name of the medication, therapeutic class/indication, reconstitution date and time, volume used to reconstitute the medication and residual volume of each vial. The data were tabulated and analyzed using descriptive statistics and the ANOVA test. Results: the residual volume of 462 (82.2%) ampoule-vials varied between 0.1 ml and 1.5 ml, whereas 165 (29.4%) ampoule-vials had 0.2 ml of residual volume, with a mean loss of 4.5% of the solution. There was no difference in the loss of solution between the different classes of drugs. Conclusion: The findings highlight the need for interventions to reduce failures in the medication preparation phases, with emphasis on errors associated with therapeutic underdosing.


RESUMEN Objetivo: Identificar volúmenes residuales en frascos ampolla luego de prepararse inyectables, asociando los errores relacionados a subdosificaciones con las clases de los medicamentos. Método: Estudio descriptivo, de abordaje cuantitativo. Datos recolectados entre diciembre de 2020 y setiembre de 2021 en servicio ambulatorio privado de un municipio brasileño del noreste del Estado de São Paulo. Fueron analizados 562 frascos ampolla de medicamentos preparados por el equipo de enfermería. Se utilizó formulario, consignando nombre comercial del medicamento, clase/indicación terapéutica, fecha y hora de reconstitución, volumen utilizado para reconstituir el medicamento y volumen residual de cada frasco. Los datos fueron tabulados y analizados por estadística descriptiva y test ANOVA. Resultados: 462 (82,2%) frascos ampolla contenían volumen residual de entre 0,1 ml y 1,5 ml, y 165 (29,4%) contenían 0,2 ml de solución residual, con una pérdida media del 4,5% de solución. No se observó diferencia de pérdida de solución entre las diferentes clases de medicamentos. Conclusión: Los hallazgos destacan la necesidad de intervenciones para reducir fallos en las fases de preparación de medicamentos, haciendo énfasis en los errores asociados con subdosificaciones terapéuticas.


Assuntos
Soluções , Preparações Farmacêuticas , Enfermagem , Composição de Medicamentos , Assistência Ambulatorial , Equipe de Enfermagem
20.
Physis (Rio J.) ; 32(3): e320311, 2022. tab
Artigo em Português | LILACS | ID: biblio-1406245

RESUMO

Resumo O mapeamento dos comportamentos frente ao uso de medicamentos informa as condições pelas quais um tratamento farmacológico é implementado. A localização da adesão à medicação como um problema clínico, evoca, no entanto, lugares bem demarcados quanto aos procedimentos para sua explicação e resolução. Nesse sentido, este trabalho busca problematizar os elementos fundantes do estudo da adesão à medicação, considerando que tal prática é hegemonicamente assimilada apenas por parâmetros científicos e biológicos, sem a inclusão de uma abordagem direcionada às especificidades históricas e culturais dos pacientes. Transferem-se, assim, a primazia da delimitação e a explicação da realidade ao próprio analista. Porém, o trabalho de campo demonstrou uma diversidade de posturas e agenciamentos quanto ao uso dos medicamentos, capaz de indicar que a geografia do cuidado não se orienta apenas a partir de um percurso linear, mas se apoia em espaços ambulantes e itinerantes, instalando-se em um campo paradoxal que mescla reprodução e criação.


Abstract The mapping of behaviors towards the use of medicines informs the conditions under which a pharmacological treatment is implemented. However, the location of medication adherence as a clinical problem evokes well-demarcated place as to the procedures for its explanation and resolution. In this sense, this work aims to problematize the founding elements of the study of medication adherence, considering that such practice is hegemonically assimilated only by scientific and biological parameters, without the inclusion of an approach directed to the patients' historical and cultural specificities. In this way, the primacy of delimitation and explanation of reality is transferred to the analyst. However, the field work showed a diversity of attitudes and management of medicines, capable of indicating that the geography of care is not oriented only from a linear path, but is supported by wandering and itinerant spaces, installing in a paradoxical field that mixes reproduction and creation.


Assuntos
Humanos , Farmacêuticos , Assistência Farmacêutica , Tratamento Farmacológico , Uso de Medicamentos , Adesão à Medicação/psicologia , Atenção Secundária à Saúde , Brasil
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA